Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 15% in early trading, driven by the upcoming IPO on the STAR Market and a recent partnership with Merck for antibody development [1] Group 1: IPO Details - Baiaosaitu plans to raise 1.185 billion yuan through its STAR Market IPO, with funds allocated for early drug development services, antibody drug research, preclinical and clinical research projects, and to supplement working capital [1] - The IPO review is scheduled for September 24, marking a critical milestone for the company [1] Group 2: Partnership with Merck - Earlier this month, Baiaosaitu signed an evaluation agreement with Merck to develop antibody-conjugated lipid delivery solutions for nucleic acid drugs [1] - Under the agreement, Baiaosaitu will provide fully human antibodies developed on its RenMice platform for Merck to assess their feasibility for antibody-conjugated lipid nanoparticle formulations [1] - Merck has been granted exclusive rights to acquire selected antibody assets, while Baiaosaitu is entitled to receive corresponding fee payments, sales shares, and sublicensing royalties [1]
港股异动 早盘涨超15% 科创版IPO即将上会 公司月初与默克达成抗体授权合作